ABOUT HYPOSAFE
HypoSafe was founded in 2005 by one of the world’s leading diabetes scientists, Professor Henning Beck-Nielsen, with a mission to help individuals suffering from hypoglycemic attacks. Through his research professor Beck-Nielsen found that hypoglycemia could be predicted timely and reliably from the EEG patterns in the brain. This insight led to the basic concept of the HypoSafe device. Beck-Nielsen and CEO Rasmus Stig Jensen decided to turn the HypoSafe device into a product to help millions of diabetic patients.
In 2005 the company was a reality and now in 2009 a device for clinical testing is being completed.
OUR MISSION
HypoSafe’s purpose and existence is built on the foundation of the following mission statement:
HypoSafe A/S is committed to improve the lives of patients at risk from hypoglycemia, by making available a timely and secure warning system combining advanced EEG measurement technologies and mathematical algorithms to detect bio-specific patterns in the human brain.
OUR VISION
HypoSafe’s vision for the future is as follows:
HypoSafe improves the lives of critically sick people, using the brain as biosensor, to detect and warn patients against the threat of critical events, resulting from their sickness. HypoSafe will closely follow the possibilities adherent within the market and follow a build-and-divest strategy, selling components of technology to interested acquires, while still retaining the core EEG measurement technology in order to allow the development of solutions for other attractive areas.
ORGANISATIONAL STRUCTURE
HypoSafe consists of a core team of directors and specialist. Between them, the core team possesses world-class competences within the areas of: diabetes, mathematics, project management and venture value creation. The core team works in close collaboration with a large number of stakeholders, all of whom are in possession of critical insight within a specific discipline. These stakeholders include: a Scientific Advisory Board, a number of participating hospitals, a technology network and major business partners within design and production.
HYPOSAFE A/S MANAGEMENT TEAM
Henning Beck-Nielsen (Chairman): Henning is a Professor and manager of the department of endocrinology at Odense University Hospital, and has been specializing in diabetes for the last 30 years. Henning has a high international reputation for his scientific work and has received a number of acknowledgements and prices. Latest he received The Hagedorn and Novo Nordisk prices. Henning is the original founder of HypoSafe A/S and is, with his strong scientific ballast, responsible for the precision and validity of the projects research related results. Renowned in the world of diabetes, Henning ensures a high level of interest around the project.
Rasmus Stig Jensen (CEO): Rasmus Stig Jensen is educated as an engineer from Aalborg Universitet. Rasmus has approximately 15 years experience with project management and execution of large scale, cross-border R&D projects and client contracts. Among those, Rasmus has five years of experience in line management and project portfolio management. In taking the role of CEO, Rasmus is responsible for all daily operations at HypoSafe A/S, with special focus on project management and delivery, and, managing relationships.
Claus Christiansen (Non-executive Director): Dr. Claus Henrik Christiansen holds a medical degree from the University of Copenhagen (1971) and has published more than 800 scientific articles. He is the executive director of Nordic Bioscience A/S, a company dedicated to the development, production and marketing of products within osteoporosis and diabetes. In addition, he is the founder of several biotechnology companies, including CCBR, Nordic Bioscience, Osteometer, MediTech and Synarc. He also serves on the board of various biomedical companies and is a member of numerous scientific advisory boards. Renowned in the biotech-business Claus manages the market and investment strategies.
Kurt Christiansen (Non-executive Director): Kurt Christiansen has many years of experience in high-level positions in a number of industrial and market oriented companies. Kurt is currently CEO of Micromatic A/S, a company of more than 1000 employees with a worldwide presence and distribution channels. Based on his experience within top management Kurt manages the transformation of HypoSafe into an international market driven organization. Further to this, Kurt manages the strategic approach to contract, legal and patent issues.
Rasmus Elsborg Madsen (Scientific Specialist): Rasmus Elsborg Madsen has a Ph.D in mathematical modelling from the Institute for Mathematical Modelling (IMM), DTU. Furthermore, Rasmus has a degree as an electrical engineer from Århus Teknikum. Rasmus’s experience within the areas of neurological networks and pattern recognition, combined with his knowledge within the area of electronics, will ensure that the medical research results can be practically transferred to the commercial device. Rasmus provides a bridge between the medical findings and the technological solution.
Claus Juhl (Medical Manager): Dr. Claus B. Juhl, MD, PhD is a Medical Doctor from the University of Århus and did his Ph.D in Århus on the subject of insulin secretion in type 2 diabetes. Claus has done extensive research and has published numerous articles in international journals. Claus has more than 15 years of experience as a diabetes doctor which ensures a comprehensive understanding of the needs and problems of being a diabetes patient. As medical director of Hyposafe he designs and oversees the required clinical testing of the hyposafe devices.
Mads Frisenborg Marker (Manager QA and regulatory affairs): Mads Frisenborg Marker has a master’s degree in engineering from the Technical University of Denmark (DTU) and an MBA degree from the Bocconi Business school (Italy). Mads has worked 7 years in the Management consulting business and has worked as project manager on numerous international projects focused on organizational alignment and performance measurement . In his current role Mads handles all quality and regulatory issues in Hyposafe as well as liaisons with business partners.